From developing new vaccines to uncovering drug targets, researchers at VIDO are working to combat tuberculosis, a persistent global health threat that remains one of the leading infectious killers worldwide.
VIDO reflects on its response to the COVID-19 pandemic and how that work continues to shape Canada’s preparedness for future health threats.
Whether partners are at an early-stage biotech building their first vaccine candidate or an established company expanding their infectious disease pipeline, progress depends on one thing: the right partner that can transform promising science to proven results.
Pandemic preparedness has never been more important, and researchers at the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan (USask) are exploring new research and response strategies with the support of government funding.
The Vaccine Development Centre at USask’s VIDO provides the expertise and infrastructure to ensure Canada is ready to respond quickly to emerging health threats and support national security.
Funding from the provincial and federal government is enabling VIDO to advance animal health research and engagement with livestock producers across Saskatchewan.
